Erasca (ERAS) Cash from Financing Activities (2020 - 2026)
Erasca posted quarterly Cash from Financing Activities of $244.7 million for Q1 2026, up 741306.06% year-on-year from N/an in Q1 2025, and up 42450.26% on a QoQ basis from $575000.0 in Q4 2025.
Erasca (ERAS) has 7 years of Cash from Financing Activities data on file, last reported at $244.7 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 741306.06% year-over-year to $244.7 million; the trailing twelve-month figure through Mar 2026 stood at $245.7 million (up 5.1% YoY), and the FY2025 full-year result was $1.1 million, down 99.54% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $244.7 million, up from $575000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $244.7 million in Q1 2026 and bottomed at $7000.0 in Q3 2023.
- The 5-year median for Cash from Financing Activities is $575000.0 (2025), against an average of $34.5 million.
- The widest annual swing landed in 2022, when Cash from Financing Activities plunged 99.87%; it then surged 741306.06% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at $96.2 million in 2022, then tumbled by 99.53% to $456000.0 in 2023, then surged by 75.66% to $801000.0 in 2024, then decreased by 28.21% to $575000.0 in 2025, then surged by 42450.26% to $244.7 million in 2026.
- The last three Cash from Financing Activities figures came in at $244.7 million (Q1 2026), $575000.0 (Q4 2025), and $41000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 244.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 244.66 Mn |
| Mar 31, 2026 | 244.66 Mn |
| Dec 31, 2025 | 575,000.00 |
| Dec 31, 2025 | 575,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Dec 31, 2024 | 801,000.00 |
| Dec 31, 2024 | 801,000.00 |
| Sep 30, 2024 | 21.10 Mn |
| Sep 30, 2024 | 21.10 Mn |
| Jun 30, 2024 | 211.87 Mn |
| Jun 30, 2024 | 211.87 Mn |
| Mar 31, 2024 | 6.93 Mn |
| Mar 31, 2024 | 6.93 Mn |
| Dec 31, 2023 | 456,000.00 |
| Dec 31, 2023 | 456,000.00 |
| Sep 30, 2023 | 7,000.00 |
| Sep 30, 2023 | 7,000.00 |
| Jun 30, 2023 | 649,000.00 |
| Jun 30, 2023 | 649,000.00 |
| Mar 31, 2023 | 183,000.00 |
| Mar 31, 2023 | 183,000.00 |
| Dec 31, 2022 | 96.20 Mn |
| Dec 31, 2022 | 96.20 Mn |
| Sep 30, 2022 | 427,000.00 |
| Sep 30, 2022 | 427,000.00 |
| Jun 30, 2022 | 992,000.00 |
| Jun 30, 2022 | 992,000.00 |
| Mar 31, 2022 | 460,000.00 |
| Mar 31, 2022 | 460,000.00 |
| Dec 31, 2021 | 1.11 Mn |
| Dec 31, 2021 | 1.11 Mn |
| Sep 30, 2021 | 317.57 Mn |
| Sep 30, 2021 | 317.57 Mn |
| Jun 30, 2021 | 180,000.00 |
| Jun 30, 2021 | 180,000.00 |
| Mar 31, 2021 | 120.54 Mn |
| Mar 31, 2021 | 120.54 Mn |
| Dec 31, 2020 | -111,000.00 |
| Dec 31, 2020 | -111,000.00 |
| Sep 30, 2020 | 14.61 Mn |
| Sep 30, 2020 | 14.61 Mn |